Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 11, 1998, Pages 781-783

  Vazquez, J A ^a   Gupta, S ^a   Villanueva, A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ARTICLE; CANDIDIASIS; CASE REPORT; CLINICAL TRIAL; HUMAN; MOUTH MUCOSA; OROPHARYNX; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS, ORAL; DRUG THERAPY, COMBINATION; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; MICROBIAL SENSITIVITY TESTS; OROPHARYNX; PILOT PROJECTS;

EID: 0032440451     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050185     Document Type: Article

References (16)

1. Vazquez JA, Sobel JD: Epidemiologic overview of resistance to oral antifungal agents in the immunocompromised host. Excerpta Medica Abstract Journals, Elsevier Science B.V., Amsterdam (1997) pp 1-11
2. Le TP, Touazon CV, Levine M, Boran M, Rollhauser C: Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for Candida esophagitis. Clinical Infectious Diseases (1996) 23:649-650
3. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C: Emergence of azole resistance in Candida species from HIV- infected patients receiving prolonged fluconazole therapy for oral candidiasis. Journal of Antimicrobial Chemotherapy (1995) 35:103-114
4. Frumkin LR, Dale DC: The role of colony stimulating factors in HIV disease. The AIDS Reader (1996) 3 nn: 185-193
5. Mitsuyasu RT: Clinical uses of hematopoietic growth hormones in HIV-related illnesses. AIDS Clinical Review (1993-1994) 3 nn: 189-212
6. Lee F, Yokota T, Otsuka T, Gemmell L, Larson N, Luh J, Arai K, Rennick D: Isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells. Proceedings of the National Academy of Sciences of the USA (1985) 82:4360-4364
7. Lechner AJ, Lamprech KE, Potthoff, Tredway TL, Matuschak GM: Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. American Journal of Physiology (1994) 266:561-568
8. Richardson MD, Brownlie CED, Shankland GS: Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF activated human neutrophils. Journal of Medical and Veterinary Mycology (1992) 30:433-441
9. Liles CW, Huang JE, van Burik Jo-Anne H, Bowden RA, Dale DC: Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. Journal of Infectious Diseases (1997) 175:1012-1015
10. Roilides E, Pizzo PA: Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clinical Infectious Diseases (1992) 15:508-524
11. Cohen MS: The evolving role of colony stimulating factors and other biotherapies in infection. Molecular events in the activation of human neutrophils for microbial killing. Clinical Infectious Diseases (1994) 18, Supplement 2:170-179
12. Dale DC: The evolving role of colony stimulating factors and other biotherapies in infection. Potential role of colony stimulating factors in the prevention and treatment of infectious diseases. Clinical Infectious Diseases (1994) 18, Supplement 2:180-188
13. Nelson S: The evolving role of colony stimulating factors and other biotherapies in infection. Role of G-CSF in the immune response to acute bacterial infection in the non-neutropenic host: an overview. Clinical Infectious Diseases (1994) 18, Supplement 2:197-204
14. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. NCCLS, Wayne, PA (1997)
15. Quereda C, Polanco AM, Giner C, Sanchez-Sousa A, Pereira E, Nava SE, Portun J, Guerrero A, Baquero F: Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV infected patients. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:30-37
16. Davison FD, Kaczmarsk RS, Pozniak A, Mufti GJ, Sutherland S: Quantification of HIV by PCR in monocytes and lymphocytes in patients receiving antiviral treatment and low dose recombinant human granulocyte macrophage colony stimulating factor. Journal of Clinical Pathology (1994) 47:855-857